Overview

• US specialty pharma firm's Q1 revenue rose 449% yr/yr on increased Arbli product orders

• Gross margin expanded to 95.6% from 6.6% on higher Arbli sales

• Company posted Q1 net loss of $3.4 mln as operating expenses held steady

Outlook

• Company expects launch of REZENOPY(TM) to impact results in second half of 2026

• Scienture says recent debt financing supports growth and financial flexibility

• Company aims for profitability in 2027

Result Drivers

• ARBLi ORDERS - Q1 revenue and gross margin gains driven by incremental product orders for Arbli, following its commercial launch in late 2025

• PRESCRIPTION GROWTH - Company saw continued month-over-month growth in both prescriptions and units sold for Arbli

Company press release: ID:nGNX5RGbB1

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Gross Margin		95.6%
Q1 Gross Profit		$54,000
Q1 Operating Expenses		$3.56 mln

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Scienture Holdings Inc is $1.50, about 272.2% above its May 15 closing price of $0.40

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.